Showing results (51-60 of 193) with videos related to
Sort By:
Pageof 20
Current Radiopharmaceuticals|October 13, 2020
Nuclear Imaging of Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for Potential Clinical ApplicationsBoudewijn J Krenning, Kim van der Heiden, Dirk J Duncker, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 23, 2011
Effect of interferon-alpha treatment on [68Ga-DOTA,Tyr3,Thre8]octreotide uptake in CA20948 tumors: a small-animal PET studyFrançois-Xavier Hanin, Stanislas Pauwels, Anne Bol, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2005
Localisation and mechanism of renal retention of radiolabelled somatostatin analoguesMarleen Melis, Eric P Krenning, Bert F Bernard, et al.Pharmaceutics|January 21, 2022
Towards Complete Tumor Resection: Novel Dual-Modality Probes for Improved Image-Guided Surgery of GRPR-Expressing Prostate CancerMaryana Handula, Marjolein Verhoeven, Kuo-Ting Chen, et al.Journal of Labelled Compounds & Radiopharmaceuticals|April 10, 2019
Comparative evaluation of the new GRPR-antagonist <sup>111</sup> In-SB9 and <sup>111</sup> In-AMBA in prostate cancer models: Implications of in vivo stabilityEmmanouil Lymperis, Aikaterini Kaloudi, Panagiotis Kanellopoulos, et al.Molecules (Basel, Switzerland)|August 1, 2020
[<sup>99m</sup>Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive ModelsPanagiotis Kanellopoulos, Emmanouil Lymperis, Aikaterini Kaloudi, et al.Plos One|July 22, 2017
In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapyHo Sze Chan, Erik de Blois, Alfred Morgenstern, et al.EJNMMI Research|February 18, 2016
Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translationAikaterini Kaloudi, Berthold A Nock, Emmanouil Lymperis, et al.Molecules (Basel, Switzerland)|March 16, 2019
Comparing Gly<sup>11</sup>/dAla<sup>11</sup>-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the <sup>111</sup>In-SB3/<sup>111</sup>In-SB4 Radiotracer PairEmmanouil Lymperis, Aikaterini Kaloudi, Panagiotis Kanellopoulos, et al.Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organsCristina Müller, Flavio Forrer, Bert F Bernard, et al.Pageof 20